Plerixafor is a reversible CXCR4 antagonist that leads to a rapid release of hematopoietic stem and progenitor cells (HPSCs) from the bone marrow into the peripheral blood by interfering with the CXCL12-CXCR4 interaction. Based on two multicenter phase III studies, plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) was approved by the Food and Drug Administration for autologous HPSC mobilization in patients with multiple myeloma and non-Hodgkin’s lymphoma. We report the case of a 26-year-old man with testicular cancer who was extensively pretreated and failed to mobilize a sufficient number of HPSCs after cytotoxic chemotherapy and the administration of G-CSF and pegylated G-CSF (PEG-G-CSF). Using a combination of plerixafor, G-CSF and PEG-G-GSF after chemotherapy, a sufficient number of HPSCs could be collected for the support of 3 sequential high-dose therapies. The patient achieved a complete and uncomplicated engraftment following each cycle of HPSC-supported high-dose therapy. Patients suffering from advanced germ cell cancer may be another group that benefits from the use of plerixafor, which to date has only been approved for the treatment of multiple myeloma and lymphoma. To our knowledge, this is the first case report of successful mobilization of HPSCs with plerixafor in a patient with testicular cancer.

Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.